In summary, our findings highlight the potential of POLE mutation as a predictive biomarker for immune checkpoint blockade therapy and suggest targeted inhibition of POLE exonuclease activity as a promising approach to enhance the efficacy of anti-PD-1/PD-L1 treatment in cancers with WT POLE. This evidence concerns the gene CD274 and cancer.